High Free Cash Flow Stocks
ALKS is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
ALKERMES PLC (ALKS) Stock Price & Overview
NASDAQ:ALKS • IE00B56GVS15
Current stock price
34.84 USD
-0.21 (-0.6%)
At close:
34.84 USD
0 (0%)
After Hours:
The current stock price of ALKS is 34.84 USD. Today ALKS is down by -0.6%. In the past month the price increased by 22.89%. In the past year, price increased by 15.9%.
ALKS Key Statistics
52-Week Range25.165 - 36.48
Current ALKS stock price positioned within its 52-week range.
1-Month Range27 - 36.48
Current ALKS stock price positioned within its 1-month range.
- Market Cap
- 5.806B
- P/E
- 20.26
- Fwd P/E
- N/A
- EPS (TTM)
- 1.72
- Dividend Yield
- N/A
ALKS Stock Performance
Today
-0.6%
1 Week
+16.44%
1 Month
+22.89%
3 Months
+23.28%
Longer-term
6 Months +12.17%
1 Year +15.90%
2 Years +41.97%
3 Years +22.03%
5 Years +58.33%
10 Years -12.35%
ALKS Stock Chart
ALKS Stock Screens
ALKS currently appears in the following ChartMill screener lists.
Strong Momentum Stocks
ALKS is part of our Strong Momentum Stocks screen, indicating it has an already in confirmed uptrend.
High Quality Stocks
ALKS is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
RSI Overbought Stocks
ALKS is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
ALKS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS is one of the better performing stocks in the market, outperforming 74.43% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ALKS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. Both the health and profitability get an excellent rating, making ALKS a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALKS Earnings
On February 25, 2026 ALKS reported an EPS of 0.29 and a revenue of 384.55M. The company missed EPS expectations (-16.95% surprise) and missed revenue expectations (-1.55% surprise).
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.29
Revenue Reported384.547M
EPS Surprise -16.95%
Revenue Surprise -1.55%
ALKS Forecast & Estimates
24 analysts have analysed ALKS and the average price target is 44.4 USD. This implies a price increase of 27.44% is expected in the next year compared to the current price of 34.84.
For the next year, analysts expect an EPS growth of -135.86% and a revenue growth 22.19% for ALKS
Analysts
Analysts81.67
Price Target44.4 (27.44%)
EPS Next Y-135.86%
Revenue Next Year22.19%
ALKS Groups
Sector & Classification
ALKS Financial Highlights
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS decreased by -40.76% compared to the year before.
Income Statements
Revenue(TTM)1.48B
Net Income(TTM)241.66M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.37% | ||
| ROA | 9.72% | ||
| ROE | 13.28% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-72.38%
Sales Q2Q%-10.57%
EPS 1Y (TTM)-40.76%
Revenue 1Y (TTM)-5.25%
ALKS Ownership
Ownership
Inst Owners109.8%
Shares166.65M
Float163.30M
Ins Owners1.6%
Short Float %12.62%
Short Ratio9.4
ALKS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALKS
Company Profile
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Company Info
IPO: 1991-07-16
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 2050
Phone: 35317728000
ALKERMES PLC / ALKS FAQ
What does ALKS do?
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
What is the stock price of ALKERMES PLC today?
The current stock price of ALKS is 34.84 USD. The price decreased by -0.6% in the last trading session.
Does ALKS stock pay dividends?
ALKS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALKS stock?
ALKS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for ALKS stock?
The PE ratio for ALKERMES PLC (ALKS) is 20.26. This is based on the reported non-GAAP earnings per share of 1.72 and the current share price of 34.84 USD.
What is ALKERMES PLC worth?
ALKERMES PLC (ALKS) has a market capitalization of 5.81B USD. This makes ALKS a Mid Cap stock.
Can you provide the ownership details for ALKS stock?
You can find the ownership structure of ALKERMES PLC (ALKS) on the Ownership tab.